Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.
Aged
Aged, 80 and over
Databases, Factual
Female
Follow-Up Studies
Humans
Leukemia
/ epidemiology
Leukemia, Hairy Cell
/ epidemiology
Leukemia, Lymphocytic, Chronic, B-Cell
/ epidemiology
Lymphoma, Non-Hodgkin
/ epidemiology
Male
Middle Aged
Neoplasms, Second Primary
/ epidemiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ epidemiology
Prognosis
Registries
Risk Assessment
/ methods
Sarcoma, Kaposi
/ epidemiology
Skin Neoplasms
/ epidemiology
Sweden
/ epidemiology
B cell leukaemia
bi-directional risk
immune suppression
mechanistic implication
second cancers
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
25
10
2018
accepted:
12
12
2018
pubmed:
2
2
2019
medline:
6
5
2020
entrez:
2
2
2019
Statut:
ppublish
Résumé
Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks (RRs) were calculated for any SPCs in patients with chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy cell leukaemia (HCL) and the risks of these leukaemias as SPCs. After CLL, RRs were significant for 20 SPCs, and high for skin squamous cell cancer (24·58 for in situ and 7·63 for invasive), Merkel cell carcinoma (14·36), Hodgkin lymphoma (7·16) and Kaposi sarcoma (6·76). Conversely, 15 CLL cancer pairs were reciprocally increased. The increased risks were reciprocal for ALL and four cancers. RR for ALL was 15·35 after myeloid neoplasia. HCL showed reciprocally increased RRs with non-Hodgkin lymphoma and melanoma. The concordance between RRs for bi-directional associations between CLL and different cancers, and HCL and different cancers was highly significant. For CLL (also for HCL), the bi-directional risks with skin cancers and other immune-related cancers suggest the probable involvement of immune dysfunction. For ALL, treatment may contribute to risks of multiple SPCs. Increased risk of ALL after haematological neoplasms may indicate bone marrow dysfunction. These findings may help guide treatment decisions and prognostic assessment.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
232-239Informations de copyright
© 2019 British Society for Haematology and John Wiley & Sons Ltd.